Novel therapies for meningiomas

Area of Science:

• Neuro-oncology
• Molecular biology
• Neurosurgery

Background:

• Meningiomas are tumors arising from the meninges, the membranes surrounding the brain and spinal cord.
• While surgery, radiation therapy, and stereotactic radiosurgery improve outcomes, a subset of patients exhibit resistance to these conventional treatments.
• Existing chemotherapeutic agents like hydroxyurea and alpha-interferon offer limited efficacy for refractory meningiomas.

Purpose of the Study:

• To review the emerging novel therapeutic strategies for meningioma treatment.
• To focus on the potential role of targeted molecular agents in managing refractory meningiomas.
• To provide an overview of new treatment avenues for patients with limited conventional therapy options.

Main Methods:

• Literature review of recent scientific publications and clinical trials.
• Analysis of studies investigating novel therapeutic agents, particularly targeted molecular therapies.
• Synthesis of information on the efficacy and mechanisms of action of emerging treatments for meningiomas.

Main Results:

• Conventional therapies are insufficient for a significant proportion of meningioma patients.
• Chemotherapeutic agents like hydroxyurea and alpha-interferon have shown minimal benefit.
• Emerging novel therapies, especially targeted molecular agents, represent a promising area for future meningioma treatment.

Conclusions:

• There is a critical need for more effective treatments for therapy-resistant meningiomas.
• Targeted molecular therapies are showing potential as a new class of drugs for meningiomas.
• Further research and clinical investigation into novel agents are warranted to improve patient outcomes.